Stoke Therapeutics, Inc.STOK
Price (close)
$25.29
Market cap
$1.6B
P/E
—
Revenue (TTM)
$27.6M
Net income
-$207.9M
Dividend yield
—
1-year total return
10.2%
Net margin
-753.6%
Revenue growth
-86.2%
Debt / equity
—
What Stoke Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $12.4M | $8.8M | $36.6M | $184.4M |
| Net income | -$52.2M | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
| Free cash flow | -$43.3M | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M |
More on STOK.
- Stoke Therapeutics, Inc. summary
- Stoke Therapeutics, Inc. financial statements
- Stoke Therapeutics, Inc. key metrics
- Stoke Therapeutics, Inc. health scores and style box
- Stoke Therapeutics, Inc. earnings
- Stoke Therapeutics, Inc. dividends
- Stoke Therapeutics, Inc. valuation
- Stoke Therapeutics, Inc. ownership and insiders
- Stoke Therapeutics, Inc. peers
Figures from Stoke Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.